60 years of practical, independent and trusted advice

DTB, the UK’s independent drug and therapeutics bulletin, is celebrating its 60th anniversary.

Since its launch as one of the first evidence-based medical publications, DTB has sought to enable healthcare professionals to make vital, impartial and trusted decisions on the harms and benefits of medicines. We reach thousands of healthcare professionals every year helping them to improve the health of patients.

Over the next few months we will be publishing a series of special articles and interviews with a focus on the importance of drug bulletins. We are also offering an exclusive 25% discount for new subscribers #DTB60

        Alerts     DTB content alerts      |      Listen      DTB podcasts      |      Subscribe      DTB subscribe 25% discount      |      Follow      DTB Twitter

David Phizackerley talks to Editorial Board member Jo Congleton about her work and involvement with DTB. Jo is a consultant in Integrated Respiratory Care at Brighton and Hove, Clinical Lead for the Kent, Surrey, Sussex Academic Health and Science Network Respiratory Programme. Her interests are in chronic respiratory conditions and reducing both variation, and inequalities, in care.                                                                                                                            

60th issue

Life begins at 60 – James Cave, Editor for DTB, considers the challenges ahead for independent drug bulletins in this editorial

Clarity to what was a confusing panoply of therapeutic choices Sir Patrick Vallance, fomer DTB Editorial Board Member, reflects on his time at DTB

Read the full issue now for free >>

Chronic hypertension in pregnancy – as part of the pregnancy series, Anja Johansen-Bibby discusses the impact and treatment of chronic hypertension

Mandatory disclosure of all pharmaceutical and medical device companies’ payments to healthcare providers – Sidney Wolfe on learnings from the USA

   “We can expect to see a significant increase in drugs coming into clinical use based on limited efficacy data and safety data that will be reliant on post-marketing surveillance and real world data…as well as an increase in…commercial arrangements with manufacturers. The need for independent scrutiny has never been more important.

                                                                                                                                                        – Dr James Cave, Editor DTB

Explore DTB’s milestones in this interactive infographic